{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:11:41Z","timestamp":1790655101829,"version":"4.1.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>\n            In patients with resistant or poorly controlled hypertension and advanced chronic kidney disease, mineralocorticoid receptor antagonists are recommended; however, hyperkalemia limits their use. BLOCK-CKD was a phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study that evaluated the safety, efficacy, and pharmacokinetics of KBP-5074, a nonsteroidal mineralocorticoid receptor antagonist, for uncontrolled hypertension in patients with stage 3b\/4 chronic kidney disease. The study tested the hypothesis that addition of KBP-5074 to standard treatment lowers blood pressure without increased risk of hyperkalemia. Patients (N=162) were randomly assigned 1:1:1 to once-daily oral treatment with placebo, KBP-5074 0.25 mg, or KBP-5074 0.5 mg. The primary end point was systolic blood pressure change from baseline at day 84. Baseline mean (SD) systolic blood pressure was 155.3 (13.55) mm\u2009Hg. After 84 days, the placebo-subtracted treatment mean difference (SE) was \u22127.0 (3.37) mm\u2009Hg with KBP-5074 0.25 mg (\n            <jats:italic>P<\/jats:italic>\n            =0.0399) and \u221210.2 (3.32) mm\u2009Hg with KBP-5074 0.5 mg (\n            <jats:italic>P<\/jats:italic>\n            =0.0026). Hyperkalemia incidence, \u22655.6 &lt;6 mmol\/L, were similar among groups 5 (8.8%) placebo, 6 (11.8%) 0.25 mg, and 9 (16.7%) 0.5 mg patients. No hyperkalemia \u22656.0 mmol\/L was observed. We conclude that KBP-5074 effectively lowers blood pressure with some risk of hyperkalemia in individuals with advanced chronic kidney disease and uncontrolled blood pressure.\n          <\/jats:p>\n          <jats:sec>\n            <jats:title>Registration:<\/jats:title>\n            <jats:p>\n              URL:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\">https:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n              ; Unique identifier: NCT03574363.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/hypertensionaha.121.17073","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T09:03:58Z","timestamp":1620637438000},"page":"74-81","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":115,"title":["Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study"],"prefix":"10.1161","volume":"78","clinical-trial-number":[{"clinical-trial-number":"nct03574363","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-1267","authenticated-orcid":true,"given":"George","family":"Bakris","sequence":"first","affiliation":[{"name":"Department of Medicine, American Heart Association Comprehensive Hypertension Center, The University of Chicago Medicine, IL (G.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo E.","family":"Pergola","sequence":"additional","affiliation":[{"name":"Renal Associates PA, San Antonio, TX (P.E.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belkis","family":"Delgado","sequence":"additional","affiliation":[{"name":"San Marcus Research Clinic, Inc, Miami Lakes, FL (B.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diyan","family":"Genov","sequence":"additional","affiliation":[{"name":"MC Comac Medical LTD EOOD, Sofia, Bulgaria (D.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Doliashvili","sequence":"additional","affiliation":[{"name":"National Institute of Endocrinology, Tbilisi, GA (T.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam","family":"Vo","sequence":"additional","affiliation":[{"name":"Mountain Kidney and Hypertension Associates, Asheville, NC (N.V.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Fred","family":"Yang","sequence":"additional","affiliation":[{"name":"KBP Biosciences, Princeton, NJ (Y.F.Y., J.M., V.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McCabe","sequence":"additional","affiliation":[{"name":"KBP Biosciences, Princeton, NJ (Y.F.Y., J.M., V.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Benn","sequence":"additional","affiliation":[{"name":"KBP Biosciences, Princeton, NJ (Y.F.Y., J.M., V.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Michigan School of Medicine, Ann Arbor (B.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the BLOCK-CKD Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000084"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2014.04.008"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz174"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61601-9"},{"key":"e_1_3_6_6_2","unstructured":"CDC Chronic Kidney Disease Surveillance System\u2014United States. Prevalence of CKD in the general population: CKD stages among US adults 1988-1994 vs. 1999-2006 vs. 2007-2014 vs. 2015-2016. Accessed January 14 2021.https:\/\/nccd.cdc.gov\/ckd\/TopicHome\/PrevalenceIncidence.aspx"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-313599"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.03.018"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1681\/A.S.N.2017020148"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00257-3"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32135-X"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000479802"},{"key":"e_1_3_6_13_2","unstructured":"Inspra. Prescribing information. Pfizer; 2020. https:\/\/www.pdr.net\/drug-summary\/Inspra-eplerenone-1817 Accessed January 16 2021."},{"key":"e_1_3_6_14_2","unstructured":"Aldactone. Prescribing information. Pfizer; 2020. https:\/\/www.pdr.net\/drug-summary\/Aldactone-spironolactone-978 Accessed January 16 2021."},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-019-0207-x"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.855"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15199"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa736"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.121.17073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:00:40Z","timestamp":1715594440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.121.17073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.121.17073"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.121.17073","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"2021-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}